Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease

Bibliography

• Rabe KF, Hurd S, Anzueto A, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176(6):532-55
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol 2008;155(3):291-9
   PubMed Web of Science ®Google Scholar
• Joos G, Geppetti P. Neural mechanisms in asthma. Eur Respir Mon 2003; 23:138-63
   Google Scholar
• Costello RW, Fryer AD. Cholinergic mechanisms in asthma. In: Barnes PJ, Grunstein MM, editors, Asthma. Lippincott-Raven, Philadelphia; 2003. p. 965-84
   Google Scholar
• Barnes PJ. Muscarinic receptor subtypes in airways. Eur Respir J 1993;6(3):328-31
   PubMed Web of Science ®Google Scholar
• Gross NJ. Cholinergic antagonists. Kay AB, Kaplan AP, Bousquet J, Holt PG. In: Allergy and allergic diseases. Wiley-Blackwell Publishing; 2008. p. 683-93
   Google Scholar
• Casarosa P, Bouyssou T, Germeyer S, Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational products. J Pharmacol Exp Ther 2009;330(2):660-8
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Belvisi MG, Mak JC, Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci 1995;56(11-12):853-9
   PubMed Web of Science ®Google Scholar
• Hvizdos KM, Goa KL. Tiotropium bromide. Drugs 2002;62(8):1195-203
   PubMed Web of Science ®Google Scholar
• Barnes PJ. The pharmacological properties of tiotropium. Chest 2000;117(2 Suppl):63S-6S
   PubMed Web of Science ®Google Scholar
• Maesen FP, Smeets JJ, Costongs MA, Ba 679 Br, a new long-acting antimuscarinic bronchodilator: a pilot dose-escalation study in COPD. Eur Respir J 1993;6(7):1031-6
   PubMed Web of Science ®Google Scholar
• Maesen FP, Smeets JJ, Sledsens TJ, Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J 1995;8(9):1506-13
   PubMed Web of Science ®Google Scholar
• van Noord JA, Smeets JJ, Custers FL, Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002;19(4):639-44
   PubMed Web of Science ®Google Scholar
• Littner MR, Ilowite JS, Tashkin DP, Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161(4 Pt 1):1136-42
   PubMed Web of Science ®Google Scholar
• Casaburi R, Briggs DD Jr, Donohue JF, The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 2000;118(5):1294-302
   PubMed Web of Science ®Google Scholar
• van Noord JA, Bantje TA, Eland ME, A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000; 55(4):289-94
   PubMed Web of Science ®Google Scholar
• Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 2004;350(26):2689-97
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Fluge T, Gerken F, Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23(6):832-40
   PubMed Web of Science ®Google Scholar
• Casaburi R, Kukafka D, Cooper CB, Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005;127:809-17
   PubMed Web of Science ®Google Scholar
• Casaburi R MD, Jones PW, Wanner A, A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24
   PubMed Web of Science ®Google Scholar
• Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003;123(5):1441-9
   PubMed Web of Science ®Google Scholar
• Vincken W, van Noord JA, Greefhorst APM, Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-16
   PubMed Web of Science ®Google Scholar
• Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006;61(10):854-62
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359(15):1543-54
   PubMed Web of Science ®Google Scholar
• Decramer M, Celli B, Kesten S, Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009;374:1129-30
   PubMedGoogle Scholar
• Caillaud D, Le Merre C, Martinat Y, A dose-ranging study of tiotropium delivered via Respimat® Soft Mist® Inhaler or Handihaler® in COPD patients. Int J COPD 2009;2:559-65
   Google Scholar
• van Noord JA, Cornelissen PJG, Aumann J-L, The efficacy of tiotropium administered via Respimat® Soft Mist® Inhaler or Handihaler® in COPD patients. Respir Med 2009;103:22-9
   PubMed Web of Science ®Google Scholar
• Donohue JF, van Noord JA, Bateman ED, A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122(1):47-55
   PubMed Web of Science ®Google Scholar
• van Noord JA, Aumann JL, Janssens E, Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005;26(2):214-22
   PubMed Web of Science ®Google Scholar
• van Noord JA, Aumann JL, Janssens E, Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006;129(3):509-17
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Littner M, Andrews CP, Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med 2008;102(4):479-87
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Kardos P, Harari S, Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008;102(11):1511-20
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Bantje TA, Luursema PB, Effects of short-acting bronchodilators added to maintenance tiotropium therapy. Chest 2007;132(5):1493-9
   PubMed Web of Science ®Google Scholar
• Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008;134(2):255-62
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PM, Seemungal TA, The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177(1):19-26
   PubMed Web of Science ®Google Scholar
• Singh D, Brooks J, Hagan G, Superiority of ‘triple’ therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008;63(7):592-8
   PubMed Web of Science ®Google Scholar
• Cazzola M, Ando F, Santus P, A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther 2007;20(5):556-61
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Fergusson D, Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146(8):545-55
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300(12):1439-50
   PubMed Web of Science ®Google Scholar
• Lee TA, Pickard AS, Au DH, Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008;149(6):380-90
   PubMed Web of Science ®Google Scholar
• FDA. Drug safety communications. Drug Safety Newsletter 2009;2(1):10
   Google Scholar
• Celli B, Decramer M, Leimer I, Cardiovascular safety of tiotropium in patients with COPD. Chest 2009. [Epub ahead of print]
   Google Scholar
• Gavalda A, Miralpeix M, Ramos I, Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther 2009;331:740-51
   Google Scholar
• Jansat JM, Lamarca R, Garcia Gil E, Ferrer P. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther 2009;47:460-8
   PubMed Web of Science ®Google Scholar
• Jansat JM, Lamarca R, de Miquel G, Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. J Clin Pharmacol 2009;49:1239-46
   PubMed Web of Science ®Google Scholar
• Schelfhout VJ, Ferrer P, Jansat JM, Activity of aclidinium bromide, a new long-acting anticholinergic agent: a phase I study. Br J Clin Pharmacol 2009 [accepted]
   Web of Science ®Google Scholar
• Joos GF, Schelfhout VJ, Kanniess F, Bronchodilatory effect of aclidinium bromide, a long-lasting anticholinergic, in COPD patients. Respir Med 2009 [accepted]
   PubMedGoogle Scholar
• Chanez P, Burge PS, Dahl R, Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm Pharmacol Ther 2009. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Hansel TT, Neighbour H, Erin EM, Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest 2005;128(4):1974-9
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J 2009;34:757-69
   PubMed Web of Science ®Google Scholar
• Powrie DJ, Wilkinson TM, Donaldson GC, Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007;30(3):472-8
   PubMed Web of Science ®Google Scholar
• Matthiesen S, Bahulayan A, Kempkens S, Muscarinic receptors mediate stimulation of human lung fibroblast proliferation. Am J Respir Cell Mol Biol 2006;35(6):621-7
   PubMed Web of Science ®Google Scholar
• Haag S, Matthiesen S, Juergens UR, Racke K. Muscarinic receptors mediate stimulation of collagen synthesis in human lung fibroblasts. Eur Respir J 2008;32:555-62
   PubMed Web of Science ®Google Scholar